KDR and neoplasm: Anlotinib is a new oral RTK inhibitor that targets VEGFR-2, VEGFR-3, FGFR1-4, PDGFR-α, PDGFR-β, c-Kit, and Ret to suppress tumor growth and angiogenesis [18], [28], [29], [30], [31].